Loading...
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized ant...
Na minha lista:
| Udgivet i: | Pharmgenomics Pers Med |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4325625/ https://ncbi.nlm.nih.gov/pubmed/25691812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S55501 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|